Perifoveal Choriocapillaris Flow Deficits Associated With Cerebrospinal Fluid Aβ<sub>42</sub>/tau in Presymptomatic Alzheimer's Disease
By identifying the transition from normal aging to presymptomatic AD, SS-OCTA metrics combined with biofluid markers could enhance AD oculomics by stratifying disease risk and prioritizing treatment interventions.
Authors
- Srinivas R. Sadda (ORCID: https://orcid.org/0000-0002-4939-3306)
- Giulia Corradetti (ORCID: https://orcid.org/0000-0001-9213-5575)
- Alfred N. Fonteh (ORCID: https://orcid.org/0000-0003-4860-5749)
- Xiaomeng Wu (ORCID: https://orcid.org/0000-0002-4534-7476)
- Astrid M. Suchy‐Dicey (ORCID: https://orcid.org/0000-0002-5608-7817)
- Jane W. Chan (ORCID: https://orcid.org/0000-0002-7120-521X)
- Xianghong Arakaki (ORCID: https://orcid.org/0000-0003-0721-7168)
- Natalie Astraea
Institutions
- Huntington Medical Research Institutes (US)
- University of California, Los Angeles (US)
- Doheny Eye Institute (US)
Publication Details
- Journal
- Translational Vision Science & Technology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1167/tvst.14.5.27
- Primary Topic
- Cerebrospinal fluid and hydrocephalus
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Biogen
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Apellis Pharmaceuticals
- Bayer HealthCare
- Carl Zeiss Meditec AG
- Astellas Pharma
- Heidelberg Engineering
- Genentech
- Samsung
- Novartis Pharma
- Janssen Pharmaceuticals